2.26
-0.0098(-0.43%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
May 11, 2015
| Name | Title | Pay | Year Born |
| Mr. Amir Reichman M.B.A., M.Sc. | Chief Executive Officer & Director | 387,000 | 1976 |
| Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer | 136,000 | 1970 |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer | 173,000 | 1971 |
| Mr. Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer | 196,000 | 1983 |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist | 201,000 | 1964 |
| Ms. Alona Tal | Head of Business Administration | 0 | N/A |
| Merav Kamensky | Head of Quality Control | 0 | N/A |
| Dr. Naama Adi Hen | Head of Quality Asurance | 0 | N/A |
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.